Stock ETNB 89BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

MarketScreener Editorial Features 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
8.07 USD -2.83% Intraday chart for 89bio, Inc. +0.62% -27.75%
May. 22 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at EASL International Liver Congress CI
May. 14 89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis CI

MarketScreener Editorial Features

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ETNB Stock
  4. News 89bio, Inc.
  5. MarketScreener Editorial Features